Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 19/20 | 0.83 |
| ▸ | ERBB4 | Q15303 | 9/20 | 0.83 |
| ▸ | ERBB3 | P21860 | 8/20 | 0.83 |
| ▸ | LCK | P06239 | 2/20 | 0.83 |
| ▸ | LYN | P07948 | 2/20 | 0.83 |
| ▸ | MET | P08581 | 2/20 | 0.83 |
| ▸ | CSK | P41240 | 2/20 | 0.83 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.83 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.83 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.83 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.83 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.83 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2749083 | 0.93 | EGFR (0.84) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL4720756 | 0.93 | EGFR (0.83) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL13253068 | 0.93 | EGFR (0.83) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL13423843 | 0.93 | EGFR (0.71) | EGFRERBB2ERBB4ERBB3LCK | |
| Hydrochloric Acid SCHEMBL3506752 | 0.92 | EGFR (0.82) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL3506376 | 0.91 | EGFR (0.81) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL3504990 | 0.91 | EGFR (0.80) | EGFRERBB2ERBB4ERBB3LCK | |
| Tak-285 SCHEMBL982278 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4ERBB3LCK | |
| Tak-285 SCHEMBL29355721 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL3505327 | 0.91 | EGFR (0.80) | EGFRERBB2ERBB4ERBB3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010036917-A1 | PREVENTION AND TREATMENT OF CANCER WITH RAS GENE MUTATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-01 | — | — | WO | disclosed |